Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies

Summary

Homozygous MTAP loss is frequently observed in oncogene-driven non-small-cell lung cancers (NSCLC), particularly in EGFR, ALK, and RET altered subtypes. While this loss did not significantly impact the response to first-line targeted therapies, it creates a selective vulnerability to PRMT5 inhibitors. Preclinical studies demonstrated that the PRMT5 inhibitor BMS-986504 is active in MTAP-deleted NSCLC models and can enhance the efficacy of existing targeted therapies. These findings suggest a novel combined therapeutic strategy for NSCLC patients with MTAP loss.

Critical appraisal

Clinical. This retrospective study on large NSCLC cohorts identifies MTAP loss as a frequent biomarker in oncogene-driven subtypes (EGFR, ALK, RET). While MTAP loss alone was not predictive of response to current first-line targeted therapies, preclinical data suggest it could identify patients who might benefit from a combination of PRMT5 inhibitors and targeted therapies. This would justify phase I/II clinical trials to evaluate this combination, with a potential clinical impact in 5+ years. Biomol: The key discovery is that MTAP loss, often co-deleted with CDKN2A, leads to partial PRMT5 inhibition, creating a selective vulnerability. The study validates the activity of the PRMT5 inhibitor BMS-986504 in preclinical models (in vitro, ex vivo, in vivo) of MTAP-deleted NSCLC, regardless of targeted therapy sensitivity. The technologies used, NGS and IHC, are established methods for MTAP status assessment, which facilitates the potential translation of this biomarker.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology